227 related articles for article (PubMed ID: 22127751)
1. Hematologic toxicities of small molecule tyrosine kinase inhibitors.
Barber NA; Afzal W; Akhtari M
Target Oncol; 2011 Dec; 6(4):203-15. PubMed ID: 22127751
[TBL] [Abstract][Full Text] [Related]
2. Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis.
Fachi MM; Tonin FS; Leonart LP; Rotta I; Fernandez-Llimos F; Pontarolo R
Br J Clin Pharmacol; 2019 Oct; 85(10):2280-2291. PubMed ID: 30907446
[TBL] [Abstract][Full Text] [Related]
3. Hematologic toxicities associated with intravenous immunoglobulin therapy.
Baxley A; Akhtari M
Int Immunopharmacol; 2011 Nov; 11(11):1663-7. PubMed ID: 21843660
[TBL] [Abstract][Full Text] [Related]
4. Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
Furuya-Kanamori L; Doi SA; Onitilo A; Akhtar S
Expert Opin Drug Saf; 2020 Feb; 19(2):223-228. PubMed ID: 31698959
[No Abstract] [Full Text] [Related]
5. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
Zhou JX; Feng LJ; Zhang X
Drug Des Devel Ther; 2017; 11():3009-3017. PubMed ID: 29075104
[TBL] [Abstract][Full Text] [Related]
6. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
[TBL] [Abstract][Full Text] [Related]
7. Drug-associated disease: hematologic dysfunction.
Vandendries ER; Drews RE
Crit Care Clin; 2006 Apr; 22(2):347-55, viii. PubMed ID: 16678004
[TBL] [Abstract][Full Text] [Related]
8. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.
Schutz FA; Je Y; Choueiri TK
Crit Rev Oncol Hematol; 2011 Nov; 80(2):291-300. PubMed ID: 21339073
[TBL] [Abstract][Full Text] [Related]
9. Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology.
Fujita KI; Ishida H; Kubota Y; Sasaki Y
Curr Drug Metab; 2017; 18(3):186-198. PubMed ID: 28059038
[TBL] [Abstract][Full Text] [Related]
10. Hematologic toxicity of sodium valproate.
Acharya S; Bussel JB
J Pediatr Hematol Oncol; 2000; 22(1):62-5. PubMed ID: 10695824
[TBL] [Abstract][Full Text] [Related]
11. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.
Resteghini C; Cavalieri S; Galbiati D; Granata R; Alfieri S; Bergamini C; Bossi P; Licitra L; Locati LD
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):349-361. PubMed ID: 28911730
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems-Based Approaches.
Brown SA; Nhola L; Herrmann J
Clin Pharmacol Ther; 2017 Jan; 101(1):65-80. PubMed ID: 27806435
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.
Dasanu CA; Padmanabhan P; Clark BA; Do C
Expert Opin Drug Saf; 2012 May; 11(3):445-57. PubMed ID: 22469002
[TBL] [Abstract][Full Text] [Related]
14. [Effects of EGFR-TKIs on sequential pemetrexed
for advanced pulmonary adenocarcinoma].
Wang X; Liu Y; Gao Z; Jiang Y; Han B; Jiang L
Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):294-8. PubMed ID: 22613336
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary toxicities of tyrosine kinase inhibitors.
Peerzada MM; Spiro TP; Daw HA
Clin Adv Hematol Oncol; 2011 Nov; 9(11):824-36. PubMed ID: 22252615
[TBL] [Abstract][Full Text] [Related]
16. Practical recommendation for rash and diarrhea management in Indian patients treated with tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Parikh P; Prabhash K; Naik R; Vaid AK; Goswami C; Rajappa S; Noronha V; Joshi A; Chacko RT; Aggarwal S; Doval DC
Indian J Cancer; 2016; 53(1):87-91. PubMed ID: 27146751
[TBL] [Abstract][Full Text] [Related]
17. Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice.
Yan M; Li W; Li WB; Huang Q; Li J; Cai HL; Gong H; Zhang BK; Wang YK
Drug Metab Rev; 2023; 55(1-2):94-106. PubMed ID: 36453523
[TBL] [Abstract][Full Text] [Related]
18. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
Terada T; Noda S; Inui K
Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
[TBL] [Abstract][Full Text] [Related]
19. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
20. Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study.
Kawazoe H; Yano A; Ishida Y; Takechi K; Katayama H; Ito R; Yakushijin Y; Moriguchi T; Tanaka M; Tanaka A; Araki H
PLoS One; 2017; 12(2):e0171066. PubMed ID: 28158216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
